Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Friday, November 11, 2022

 ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 ,inter alia, to consider and approve This is to inform you that the Meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Friday, November 11, 2022 inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2022. We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from September 16, 2022 to November 13, 2022 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. We request you to please take the same on record.
31-10-2022

Data is our lifeblood; our people the heart'

 We are using technology like digital devices to collect data directly from the patients, in a less intrusive way, says Natalie Fishburn, VP, CDI unit, AstraZeneca
30-10-2022
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Increase In Volume

 This has reference to your email dated October 28, 2022 bearing reference no. L/SURV/ONL/PV/IJ/ 2022-2023 / 265 on the captioned subject. We wish to inform you that we have no information/announcement including pending announcement which in the Company's opinion may have a bearing on the price/volume behaviour in the scrip. We thank you for drawing our attention and assure you of Company's continued adherence to its obligation under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
28-10-2022
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Clarification sought from AstraZeneca Pharma India Ltd

 The Exchange has sought clarification from AstraZeneca Pharma India Ltd on October 28, 2022, with reference to Movement in Volume.The reply is awaited.
28-10-2022

AstraZeneca covid jabs saved over 6 mn lives'

 Indian pharma industry's reputation was built over decades and we have more audits happening at all levels, says Gagandeep Singh Bedi, managing director of AstraZeneca India
28-10-2022
Bigul

BMJ study flags blood clot risk of AstraZeneca-Oxford vaccine

 Company vouches for safety profile, says benefits outweigh risk
27-10-2022

Evidence updated on blood clotting side effect of Covid-19 jab: Study

 Scientists have uncovered more knowledge about the risk of developing a very rare blood clotting condition following vaccination against COVID-19, according to a study. Based on health data from five European countries and the US, the study shows an increased risk of the condition, called thrombosis with thrombocytopenia syndrome (TTS), after first-dose of the Oxford-Astrazeneca vaccine (same as Covishield in formulation). The study, published in The British Medical Journal (BMJ), also shows a trend towards an increased risk after the Janssen/Johnson & Johnson vaccine, compared with the Pfizer-BioNTech vaccine. The researchers stressed that the syndrome is very rare, but said the observed risks "should be considered when planning further immunisation campaigns and future vaccine development." TTS occurs when a person has blood clots (thrombosis) as well as low blood platelet counts (thrombocytopenia). According to the study, it is very rare and different from general clotting...
27-10-2022
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Statement Of Investor Complaints For The Quarter Ended September 2022

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0202 Name of the Signatory :- MANASA RDesignation :- Company Secretary and Compliance Officer
17-10-2022
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the attached request for loss of share certificate from the claimant
17-10-2022
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We are enclosing herewith Certificate dated October 6, 2022 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
11-10-2022
Next Page
Close

Let's Open Free Demat Account